Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A
E.A. Coors
Department of Dermatology, University of Hamburg, Martinistr. 52, D-20246 Hamburg, Germany *Center for Dermatology, Klinikum Stuttgart, Prießnitzweg 24, D-70374 Stuttgart, Germany E-mail: [email protected]
Search for more papers by this authorP. Von den Driesch
Department of Dermatology, University of Hamburg, Martinistr. 52, D-20246 Hamburg, Germany *Center for Dermatology, Klinikum Stuttgart, Prießnitzweg 24, D-70374 Stuttgart, Germany E-mail: [email protected]
Search for more papers by this authorE.A. Coors
Department of Dermatology, University of Hamburg, Martinistr. 52, D-20246 Hamburg, Germany *Center for Dermatology, Klinikum Stuttgart, Prießnitzweg 24, D-70374 Stuttgart, Germany E-mail: [email protected]
Search for more papers by this authorP. Von den Driesch
Department of Dermatology, University of Hamburg, Martinistr. 52, D-20246 Hamburg, Germany *Center for Dermatology, Klinikum Stuttgart, Prießnitzweg 24, D-70374 Stuttgart, Germany E-mail: [email protected]
Search for more papers by this authorConflicts of interest: none
References
- 1 Dummer R, Kempf W, Hess Schmid M et al. Therapy of cutaneous lymphoma – current practice and future developments. Onkologie 2003; 26: 366–72.DOI: 10.1159/000072098
- 2 Zhang C, Hazarika P, Ni X et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002; 8: 1234–40.
- 3 Duvic M, Martin AG, Kim Y et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol, 2001; 137: 581–93.
- 4 Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II–III trial results. J Clin Oncol 2001; 19: 2456–71.
- 5 Bohmeyer J, Stadler R, Kremer A et al. Bexarotene – an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences. JDDG 2003; 1: 785–9.
- 6 Stern DK, Lebwohl M. Treatment of mycosis fungoides with oral bexarotene combined with PUVA. J Drugs Dermatol 2002; 1: 134–6.
- 7 Shapiro M, Rook AH, Lehrer MS et al. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47: 956–61.DOI: 10.1067/mjd.2002.124816
- 8 McGinnis KS, Shapiro M, Vittorio CC et al. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: an effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. Arch Dermatol 2003; 139: 771–5.DOI: 10.1001/archderm.139.6.771
- 9 Huber MA, Kunzi-Rapp K, Staib G, Scharffetter-Kochanek K. Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy. J Am Acad Dermatol 2004; 50: 475–6.DOI: 10.1016/S0190-9622(03)02488-5
- 10 Zackheim HS. Cutaneous T-cell lymphoma: update of treatment. Dermatology 1999; 199: 102–5.DOI: 10.1159/000018214
- 11 Thomsen K, Hammar H, Molin L, Volden G. Retinoids plus PUVA (RePUVA) in mycosis fungoides, plaque stage. Acta Derm Venereol 1989; 69: 536–8.
